Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.41-0.21 (-3.74%)
At close: 4:00PM EDT
5.69 +0.28 (+5.18%)
After hours: 07:15PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.62
Open5.60
Bid5.35 x 800
Ask5.70 x 900
Day's Range5.34 - 5.61
52 Week Range1.90 - 13.05
Volume321,057
Avg. Volume717,161
Market Cap181.584M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATNF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 180 Life Sciences Corp.
    Daily – Vickers Top Insider Picks for 06/29/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio

    Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)”PALO ALTO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has received a Notice of Allowance, from the United States (US) Patent and Trade Office, for app

  • GlobeNewswire

    Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications

    Three Anti-TNF Product Candidates To Be Included in Expected Global AgreementPALO ALTO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that they have entered into a Memorandum of Understanding, (“MOU”) with Celltrion Healthcare, a leading biopharmaceutical c

  • GlobeNewswire

    180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders

    PALO ALTO, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, the "Company"), a clinical-stage biotechnology company with its lead indication in Phase 2b clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. Dear Fellow Stockholder, As you may recall, I previously authored a letter to you at

Advertisement
Advertisement